Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Figure out How to Pick a SUV with Senior-Accommodating Tech Elements - 25 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- 3New Year's Eve Live: Nashville's Big Bash: How to watch the star-studded country music special live
- 4EU agrees on agriculture safeguards as fronts harden in Mercosur deal
- 5What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
- Tanzania president remorseful over internet shutdown on election day
- One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- Heart disease risk greater for women with a common condition they may not be aware they have
- Manual for Notorious Fragrances: Immortal Aromas
- Must-See Attractions in Washington, D.C.
- Watch India launch advanced military satellite on rocket's 1st flight since May 2025 failure
- Most loved Well known Accessory Styles For 2024
- The top astronomical discoveries of 2025
- Father and son spending Christmas together after health scares
